Novel Imaging Agent to Image and Quantify Beta-Cell Mass

Massachusetts General Hospital
posted on 02/26/2012

The Technology: The inventors have developed a novel imaging agent that enables the imaging and quantification of beta-cell mass in vivo. The inventors have demonstrated this agent in both in vitro cell-based assays and in vivo preclinical studies. Applications: This imaging agent allows for significantly improved evaluation of potential therapies for diabetes in preclinical and clinical research. Further, this agent could be a valuable tool for the non-invasive monitoring of diabetes (e.g. disease progression and response to treatment) in a clinical context. Advantages: - There is a large unmet clinical need to quantify beta-cell mass in vivo - currently, there is no diagnostic test to accurately detect loss of beta cell mass in vivo. - The ability to quantify beta-cell mass would enable the further study of diabetes biology, the monitoring of disease progression or response to treatment. - Potentially enables the earlier diagnosis of type 1 diabetes by distinguishing between healthy individuals and occult diabetics.

Innovation Details

File Number: 20780 

Other Information: *Investigator(s)*
Ralph Edmund ; Weissleder Thomas ; Keliher Reiner

Daniel Castro, 617-954-9325

IP Protection

License Online

This innovation currently is not available for online licensing. Please contact Beth Mollineaux at Massachusetts General Hospital for more information.

Request more info via email request more info

Case Manager:

Beth Mollineaux Beth Mollineaux

Innovations (0)

Download Technology Brief (PDF)

Followed By

Follow this innovation

No one is following this innovation.

Related Tags

Find more innovations

February 11, 2009

13,504 members 17,756 innovations 176 organizations


Alfred R Berkeley, Chairman, Pipeline Financial Group, Inc., Former President and Vice Chairman, Nasdaq Stock Market, Inc.

"Our economy is inextricably intertwined with university innovations. Unfortunately, our country’s short-term outlook often interferes with the long-term possibilities of university research and collaborations with industry and entrepreneurs..."  read more...